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Abstract
microRNAs (miRs) modulate the expression levels of mRNAs and proteins and can thus contribute to cancer initiation and
progression. In addition to their intracelluar function, miRs are released from cells and shed into the circulation. We
postulated that circulating miRs could provide insight into pathways altered during cancer progression and may indicate
responses to treatment. Here we focus on pancreatic cancer malignant progression. We report that changes in miR
expression patterns during progression of normal tissues to invasive pancreatic adenocarcinoma in the p48-Cre/LSL-
Kras
G12D mouse model mirrors the miR changes observed in human pancreatic cancer tissues. miR-148a/b and miR-375
expression were found decreased whereas miR-10, miR-21, miR-100 and miR-155 were increased when comparing normal
tissues, premalignant lesions and invasive carcinoma in the mouse model. Predicted target mRNAs FGFR1 (miR-10) and
MLH1 (miR-155) were found downregulated. Quantitation of nine microRNAs in plasma samples from patients distinguished
pancreatic cancers from other cancers as well as non-cancerous pancreatic disease. Finally, gemcitabine treatment of
control animals and p48-Cre/LSL-Kras
G12D animals with pancreatic cancer caused distinct and up to 60-fold changes in
circulating miRs that indicate differential drug effects on normal and cancer tissues. These findings support the significance
of detecting miRs in the circulation and suggests that circulating miRs could serve as indicators of drug response.
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Introduction
microRNAs (miRNAs or miRs) are small, non-coding RNAs
that play a significant role in controlling the activities of cellular
pathways both in physiology and pathology (see e.g. [1]). The
distinct function of miRs in different cancers has become more
obvious over the past years [2,3], and many studies show that miR
signatures can be used to distinguish different cancers [4,5,6,7]
prognoses [8,9,10,11,12,13] or reveal potential targets [14] as well
as altered signaling pathways [15]. Most surprisingly, a compar-
ison of miR and mRNA profiles of primary and metastatic cancer
lesions showed that miRs provided a more reliable and distinctive
signature than mRNAs and found that miR signatures were
superior to mRNAs in identifying the organ source of metastases of
unknown origin [16,17]. Beyond these analyses of normal and
diseased tissues, more recent reports have shown that miR species
can be detected in the circulation [18] and suggested that analysis
of serum samples for defined miR species could be used to identify
patients with cancers [19,20,21,22,23,24,25] as well as other
diseases such as cardiac disease [26,27,28,29,30] or diabetes
mellitus [31].
Sequences of miRs are frequently conserved across species and
we speculated that analysis of miRs in a well-defined animal model
could inform studies with patient samples. We were particularly
interested to evaluate whether this could be translated into the
detection and quantitation of miRs in the circulation because that
might ultimately reveal activated or altered disease pathways based
on the analysis of a blood sample rather than the analysis of
diseased tissue specimen [32]. In addition, treatments will likely
impact miR patterns in the circulation and these patterns may well
be useful in establishing signatures of drug effects.
Here we focused on pancreatic cancer, that was diagnosed in
43,140 patients in 2010. Pancreatic cancer is a fatal disease with a
5-year survival rate of only 6% [33]. This poor outcome is due to
late detection as well as a lack of effective therapies [34]. To
identify informative miRs, we used a genetically engineered mouse
model, the p48-Cre/LSL-Kras
G12D model, that was first described
by Hingorani et al. [35]. This model faithfully reproduces the
malignant progression seen in human PDAC development [34,35]
and numerous studies with this model narrowed down the cells of
origin of PDAC [36] and showed the contribution of different
driver genes [37,38,39] that control the biology and progression of
this disease [40]. We used tissues harvested at different stages of
malignant progression from this mouse model to evaluate a panel
of miRs that had been shown to be up- or down-regulated in
human pancreatic cancer tissues and had been reviewed and
compiled recently by Seux and colleagues [41]. This analysis was
then followed by quantitation of miRs in the circulation of patients
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expression patterns that distinguished between the different
groups. miR expression patterns in serum from experimental
animals paralleled the findings in patients. Finally, treatment of
animals with the anti-cancer drug Gemcitabine that is approved
for first line therapy of pancreatic cancer [42], showed a distinct
pattern change in miR levels in the circulation of animals with
pancreatic cancer versus controls.
Results
microRNA expression in pancreatic tissues during
Kras
G12D-induced malignant progression
A panel of miRs consistently up- or down-regulated across
different studies in human pancreatic cancer tissues relative to
normal pancreatic tissues was selected from literature and data
base searches (see Table S1; Refs [7,41,43,44,45]). For this miR
panel we established quantitative RT-PCR detection [46] because
we expected a wide range of miR concentrations when comparing
tissue extracts versus blood samples or across human and murine
samples.
Mouse pancreatic tissue samples were harvested at different
ages from the p48-Cre/LSL-Kras
G12D mouse model. Pancreatic
duct epithelia in these animals progress through early and late
dysplastic lesions, PanIN (=Pancreatic in situ carcinoma) over the
period of several months to invasive cancer and thus mimic
malignant progression of the human disease [34,35]. Each tissue
sample harvested was staged by a histologic analysis of pancreatic
ductal changes (Figure 1A). Control tissues contained 100%
normal ducts (Figure 1B). Pancreata from younger mice
(Figure 1C) contained more than 50% of ducts with early stage
dysplastic lesions (PanIN-1 or -2). Pancreata from older mice
(Figure 1D) contained ,10% of ducts with late stage dysplastic
lesions (PanIN-3) in addition to ,50% of ducts with PanIN-1 or -
2. PDAC tissues contained mostly invasive adenocarcinoma
(Figure 1E).
Analysis of the expression of individual miRs showed three
major trends (Figure 2A–C): First, expression of miR-10, miR-16,
miR-21, miR-100 and miR-155 increased in the early PanIN
lesions relative to control, and maintained high expression in the
late PanIN and adenocarcinoma tissues. (Figure 2A) Second, miR-
22, miR-148a/b, miR-212, and miR-375 were highly expressed in
control tissues and their expression was reduced in PanIN
(Figure 2C) as well as in adenocarcinoma tissues. Third, expression
of miR-29b, miR-34a/c, miR-141, miR-199, miR-210c and miR-
301a did not change significantly during malignant progression
(Figure 2B).
Distinct clustering of miRs and of pancreatic tissues with
different disease stages
An unsupervised clustering of the mouse tissues based on their
miR expression levels identified three distinct groups (Figure 2D).
The control tissues separated from all other tissues in a grouping of
their own (blue box). Five of six tissues classified as in situ lesions
(PanIN) were clustered together in a second group. Invasive
adenocarcinoma and one of the late PanIN tissues segregated into
a further cluster (yellow box). Thus, the set of miRs analyzed here
is sufficient to distinguish the different stages of mutant Kras-
induced pancreatic malignant progression.
Unsupervised clustering of the individual miRs was performed
to determine which miRs behave in parallel and can thus serve as
common signatures coincident with disease stage (Figure 2E). One
group (yellow box) contained those miRs that showed the highest
expression in the adenocarcinoma tissues and the lowest in the
control tissues. A separate group (blue box) showed a reciprocal
miR expression pattern, with the highest levels in control tissues
and the lowest levels in adenocarcinoma. These groupings suggest
that a subset of miRs can define a tissue’s classification
corroborating earlier work from others with different human
cancer samples [16,17].
A comparison of the findings in the mouse model (Figure 1 & 2)
with published studies in human pancreatic cancers shows the
same qualitative changes for most of twelve miRs analyzed in both
settings (Table S1; Refs [7,43,44,45]): Seven miRs upregulated in
cancer versus normal tissues in the mouse model were also
upregulated in human cancers. Of five miRs found downregulated
in the mouse model, four were also downregulated or showed no
change in studies with human specimen. Only miR-212 was
upregulated in human and downregulated in mouse PDAC
samples. It is tempting to speculate that the discordance of miR-
Figure 1. Malignant progression of pancreatic duct epithelia in
p48-Cre/LSL-Kras
G12D mice. (A) Quantitation of histopathologic
alterations in the pancreata of controls or p48-Cre/Kras
G12D mice. The
samples were separated into controls, early stage dysplastic lesions
(PanIN-1 and -2), late stage dysplastic lesions (PanIN-3 present) and
invasive pancreatic duct adenocarcinoma (PDAC). (B to E) Representa-
tive histopathology images from each of the groups: (B) normal
pancreas, (C) PanIN-1 and -2 (early), (D) PanIN-3 (late) and (E) PDAC.
Mean 6 standard error of the % of the pancreatic tissue with the
respective lesions is shown (n=3 animals for each group). 0, not
detected.
doi:10.1371/journal.pone.0020687.g001
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species differences of epithelial-stroma interactions during malig-
nant progression [47]. Overall, the close coincidence of miR
changes in malignant pancreatic tissues across species and across
different studies suggests that clinical pancreatic adenocarcinoma
is represented well by the p48-Cre/LSL-Kras
G12D animal model.
Expression of miR target genes and miRs in mouse
pancreatic tissues
Recent studies have shown that the predominant activity of
miRs (84%) is their impact on target mRNA steady-state levels
[48]. To assss this in the mouse model, we identified candidate
mRNA targets from an unbiased list of under-expressed mRNAs
in human pancreatic cancers and matched these with the miR
panel studied here (Table S3). The set of matching genes
downregulated in pancreatic cancer contains MLH1 as a
predicted target for miR-155, and FGFR1 as a target of miR-
10. In a comparison of normal and cancer tissues harvested from
the mouse models mRNA expression of MLH1 and of FGFR1
showed a significant, inverse relationship miR-155 and miR-10
respectively (Figure 3).
Gemcitabine treatment effect on circulating miRs in the
animal model
The presence of diseased tissues may be indicated by altered
miR concentraions in the circulation (see Introduction). As a
logical extension, miR concentrations in the circulation could also
serve as easily accessible markers of treatment efficacy and even
indicate pathways altered by a given treatment. We tested this
hypothesis in the PDAC mouse model relative to control animals
without cancer. Gemcitabine is a first-line drug used in the
treatment of patients with pancreatic cancer and was administered
Figure 2. miR expression in mouse pancreatic tissues during malignant progression. (A–C) Expression levels of individual miRs in control
and pancreatic tissues at different stages of malignant transformation. The miRs levels were grouped as increasing (A), steady (B), or decreasing (C)
based on a comparison of the levels in each group (n=3 per group). Mean 6 standard error is shown for each miR expression. (D) Hierarchical
clustering of mouse tissues based on miR expression. Distinct groups are indicated by the blue and the yellow box. (E) Hierarchical clustering of miRs
based on their expression levels. miRs that were expressed at high levels in control (blue box) versus PDAC tissues (yellow box) are indicated.
*p ,0.05, ** p,0.01, *** p,0.001; control vs. early PanIN, late PanIN, or PDAC. #:a u.0.85 and p=0.06, ##:a u.0.85 and p,0.05, ###:a u.0.90
and p,0.01. (au, approximately unbiased probability).
doi:10.1371/journal.pone.0020687.g002
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animals. The dose and treatment schedule were adapted from other
studies that had shown efficacy over a longer treatment period
[49,50]. A small blood sample (,0.1 ml ) was drawn before
initiationoftreatmenttocompare miRserum levels beforeandafter
treatment across these two groups of animals. The presence of
PDAC in the p48-Cre/Kras
G12D animals was confirmed by
histological analysis of pancreatic tissues at the end of the study.
We selected six miRs that were found upregulated and two that
were down regulated in PDAC tissues relative to controls (see
Figure 2). A.10,000-fold concentration range of these eight miRs
was found in the circulation of animals (Figure 4A). Before
treatment (Figure 4A, open bars), serum levels of miR-10 and
miR-155 were elevated .2-fold (p,0.05) in the PDAC (red) versus
control group (black). In contrast, serum levels of miR-21, miR-
148b and miR-375 where indistinguishable between the groups.
Gemcitabine treatment (Figure 4A, filled bars) reduced serum levels
of miR-10, miR-21 and miR-155 in animals with PDAC and in
controls by 6- to 60-fold(p,0.05 to ,0.01; Figure 4B). Serum levels
of miR-100 and miR-375 were reduced by .2-fold after the
treatment though only the controls showed statistically significant
differences(p,0.05). miR-148b serum levelswere not altered bythe
treatment and miR-16 levels increased .5-fold after treatment. It is
noteworthy that Gemcitabine treatment of animals with PDAC
reduced serum levels of miR-21, miR-10 and miR-155 by an
additional 2-, 3- and 6-fold below the reduction seen in control
animals, although only the miR-155 reached statistical significance
in the comparison of PDAC and control (Figure 4B; p,0.05). This
data suggests that monitoring appropriate miRs in the circulation
may distinguish drug effects on diseased tissues from the drug effects
on the healthy non-target tissues.
miRs in the circulation of patients with pancreatic and
other cancers
Nine different miRs were isolated and quantitated from plasma
samples of patients with pancreatic cancers, other gastrointestinal
cancers, and non-cancer controls. The patient diagnoses are
summarized in Table S2. miR-100a and miR-10 were significantly
increased in the pancreatic cancer patients compared to non-
cancer controls while a number of the other miRs (miR-16, 21,
155, 199, 221, and 223) showed a trend of increased expression
that did not reach statistical significance (Figure 5A). Another
subset of miRs showed significant expression differences between
pancreatic cancer and colon cancer patients, but not relative to
patients with other gastrointestinal cancers. The expression
patterns of the different circulating miRs suggest that some are
best at distinguishing between cancer and non-cancer patients
whilst others best distinguish the diseased organs.
In an unsupervised random forest analysis that considered the
expression of all nine miRs isolated from the circulation, five of six
pancreatic cancer patients grouped together in a separate group
from the majority of other patients (Figure 5B). This confirms that
the combined expression pattern of these nine miRs in the
circulation was sufficient to identify patients with pancreatic
cancer as separate from patients with other GI cancers and
controls. Of note were two specimens from patients with duodenal
neoplasms (arrows) that grouped closest to pancreatic cancer
patients, possibly due to pancreatic involvement undetected at the
time of sampling. Also, samples from patients with non-cancerous
pancreatic disease and non-cancer controls grouped together
indicating that the panel of miR expression is specific for
pancreatic cancer rather than any disease originating from the
pancreas.
Discussion
The mutant Kras
G12D–driven pancreatic cancer model has
been well characterized at numerous molecular and biological
levels [35,36,37,38,39]. Our analysis of tissue samples shows that
some miR changes associated with invasive pancreatic cancer are
already apparent during the early stages of the disease (Figure 2).
More surprising was the extent to which changes in miR
expression in the animal model mimicked miR expression changes
observed in human pancreatic cancer (see Table S1). Indeed, a
subset of miRs that includes miR-10 and miR-155 were
upregulated in pancreatic cancer tissues of patients and mice as
well as in the respective blood samples. Thus, this study provides
evidence that the inter-species similarity of miR expression in the
context of pancreatic cancer is relatively conserved, very likely due
to mutant Kras as a major initiator of this malignancy [42].
The comparative analysis of miR expression during malignant
progression in the mouse model allows us to draw some
Figure 3. Correlation between the expression of predicted mRNA target genes and miRs in mouse normal and pancreatic cancer
tissues (PDAC). Tissues from p48-Cre/Kras
G12D mice with invasive pancreatic ductal adenocarcinoma (PDAC) and normal pancreata were analyzed
for expression of miR-10 and miR-155 relative to the respective candidate target mRNAs, FGFR1 and MLH1 using quantitative RT-PCR. Mean 6 SEM of
n=3 in each group; ***, P,0.001 normal versus cancer.
doi:10.1371/journal.pone.0020687.g003
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indicate the presence of precursor lesions. Habbe et al. [51]
reported on the expression levels of miRs in human intraductal
papillary mucinous neoplasms (IPMN) tissues, and concluded that
miR-155 is upregulated and a possible tissue biomarker of pre-
invasive disease. We found miR-155 to be upregulated in the sets
that contain PanIN lesions in the mouse model and also found
miR-155 upregulated in plasma samples from pancreatic cancer
patients. Other studies evaluating circulating miR-21, miR-210,
miR-155 and miR-196a in different sets of pancreatic cancer
patients have drawn similar conclusions on the diagnostic potential
of miRs [52]. IPMN, mucinous cystic neoplasm (MCN), and
PanIN represent three known precursor lesions of PDAC. These
three types of premalignancies have many genetic and pathologic
similarities, but also some features that allow to differentiate them
[53]. Our findings support the hypothesis that plasma levels of
miR-155 may indeed represent a biomarker indicating the
presence of PanIN lesions.
Similar miR changes in tissues and in the circulation suggest to us
that miRs are released from the diseased tissues in a continuous
manner possibly via exosomes [54,55] although there may be specific
releasemechanismsthatmayfavorsomemiRsoverothers[56].Here
we mostlyfocused on miRs that are elevated in diseased tissues rather
than those whose expression is reduced or lost. We reasoned that a
loss of a given miR will only impact on steady-state levels in the
circulation if the diseased organ is the major source of the miR
present in the circulation. E.g. miR-148a/b and miR-375 are
downregulated very strongly in pancreatic cancer relative to normal
pancreatic tissues. miR-375 has been shown to play a major role in
pancreatic islet development [57], and function as well as in the
maintenance of glucose homeostasis [58,59] and it is noteworthy that
one early symptom of PDAC can be adult onset diabetes mellitus.
miR-148 can repress expression of DNMT3b through a region in its
coding sequence [60] and can thus impact DNA repair mechanisms.
In spite of a.100-fold reduction of miR-375 and miR-148a/b
during malignant transformation of pancreatic tissues, it is striking
that their serum levels are not reduced in animals with PDAC (see
Figure 2C and 4A). This suggests that pancreatic contribution to
their serum levels is only small. This is likely also true for miR-21
where increases in tissue levels of .100-fold during pancreatic
malignant transformation in the animal model are not reflected in
increased serum levels (see Figure 2A and 4A). In contrast, miR-10
and miR-155 levels in serum are increased during pancreatic
malignant transformation in mice and in patients supporting the
notion that the diseased organ is a significant contributor to serum
levels of these miRs (see Figure 4A and 5A).
Recent studies from the Bartel laboratory have demonstrated
that the predominant activity of miRs is to decrease target mRNA
levels and found that over 84% of miR effects on protein
production are due to this depletion of target mRNA [48]. Thus,
miRs that are upregulated in the circulation of diseased subjects
may coincide with reduced levels of target mRNAs in the diseased
tissue of origin. We further hypothesized that miRs found to be
increased in the circulation of patients might be present at much
higher levels in the diseased tisses due to the dilution upon their
shedding into the blood stream. We identified candidate mRNA
targets and an unbiased list of under-expressed mRNAs from
pancreatic cancer versus normal tissues compiled from different
studies returned 154 mRNAs that could be cancer relevant miR
targets. These were matched with the miR panel studied here
(Table S3).
The set of genes returned from this analysis contains MLH1
predicted as a target for miR-155. Indeed, overexpression of miR-
155 in cell lines resulted in down-regulation of hMSH2, hMSH6,
and hMLH1. Also, an inverse correlation between expression
levels of miR-155 and MLH1 or MSH2 proteins was reported for
human colorectal cancers [61]. MLH1 is a mis-match repair
protein that contributes to the accumulation of genetic errors in
the context of familial pancreatic cancer and some sporadic cases
[34]. Its mRNA was found downregulated in pancreatic cancer
samples and a fraction of the loss of MLH1 mRNA expression in
pancreatic cancers has been attributed to promoter hypermethyla-
Figure 4. Effect of Gemcitabine treatment on serum miR levels of p48-Cre/LSL-Kras
G12D mice with PDAC (red; n=5) or age-matched
control mice (black; n=5). (A) miR-levels in serum samples harvested before (open bars) and after a one week treatment with Gemcitabine (5
doses of 40 mg/kg). (B) Ratio of serum concentrations before / after Gemcitabine treatment. The dotted line indicates a two-fold difference. *,
p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0020687.g004
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the expression of miR-155 and MLH1 mRNA in the comparison
of normal and cancer tissues (Figure 3A). In addition, FGFR1
mRNA was found downregulated in human pancreatic adenocar-
cinoma (Table S3) and we observed a significant downregulation
in the mouse PDAC model relative to normal tissues (Figure 3B).
These findings with miR-10 and miR-155 and their predicted
target mRNAs MLH1 and FGFR1 support the notion of a
potential regulatory function of these miRs during malignant
progression.
In a further series of animal studies with potential direct clinical
application, we tested whether miRs could indicate drug efficacy.
The concentration range of circulating miRs monitored in this
experiments is .10,000-fold and the impact of the drug treatment
was unrelated with the pre-treatment concentration of the eight
miRs monitored (Figure 4A). After Gemcitabine treatment miR-
16 was found increased in the serum by 5-fold in PDAC as well as
control animals. miR-16 expression is associated with apoptosis
[63], growth suppression through p53 [64] and tumor suppression
[65]. The increase of this miR-16 in the circulation cancer and
control animals matches with the cytotoxic activity of the drug on
healthy tissues. In contrast with this increase, miR-148b serum
levels were not affected after the drug treatment and serum miR-
10 and miR-155 were reduced the most (30- and 60-fold) after the
Gemcitabine treatment. These two miRs had been found elevated
in the serum of PDAC animals relative to controls before initiation
of the drug treatment. Furthermore, serum levels of miR-10 and
miR-155 in treated animals with PDAC dropped below the serum
levels of treated control animals (Figure 4A & B) suggesting them
as potential indicators of tumor specific effects of the treatment.
Overall, the findings in this experimental setting support the
concept of a pancreatic cancer selective efficacy of Gemcitabine
though effects on the homeostasis of other healthy tissues also
became apparent.
Conclusion
miR changes in tissues and the circulation show remarkable
similarities between pancreatic cancer in patients and the p48-
Cre/Kras
G12D mouse model of the disease. Beyond the mimcry of
human molecular pathology in the mouse model, the signature
Figure 5. miRs detected in human plasma samples. Samples were from pancreatic cancer patients, non-cancer controls, and patients with
other GI cancers. (A) Concentrations of nine miRs detected in the circulation show individual differences between patients groups. Note the different
ranges of the scales on the Y axes. (B) Unsupervised random forest analysis comparing pancreatic cancer (black circles) versus non-cancer controls
with pancreatic disease (white triangle), non-cancer controls without pancreatic disease (white circles), upper GI cancer (blue circles), colon cancers
(red circles), and liver cancers (yellow circles). Circled in red are the majority of the pancreatic cancers. Arrows indicate two specimen from patients
with duodenal cancer. * p,0.05, ** p,0.01, *** p,0.001. Patient characteristics are provided in Table S2.
doi:10.1371/journal.pone.0020687.g005
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drug efficacy in the development of desperately needed single
agent or combination therapies [42] of this devastating disease.
Materials and Methods
Mouse tissue analysis
Animal study protocols were approved by the Georgetown
UniversityAnimalCare and UseCommittee(GUACUC#08-028).
The p48-Cre/LSL-Kras
G12D mouse model has described previous-
ly [35]. In the control, late PanIN and adenocarcinoma groups,
mice were sacrificed at 16 months of age. Controls lacked either the
KRAS
G12D orthep48-CRE allele.Forthe early PanINgroup,mice
at onemonth of age weretreatedwithcaerulinandsacrificed atfour
months of age following an established protocol [66]. Pancreata
were bisected from tail to head with one half fixed in formalin and
the other half frozen in liquid nitrogen. A pathologist scored the
highest PanIN grade per lobule of all lobules counted in a
representative H&E stained slide of each mouse’s pancreas [35].
‘‘Normal’’ includes any normal and reactive ductal change. PanIN-
1 and -2 were combined into a single category of ‘‘early’’ lesions
while tissues with PanIN-3 were included in a separate category of
‘‘late’’ lesions due to the high likelihood of malignant progression.
miR and mRNA expression in mouse pancreatic tissue
Total RNA was extracted from tissues using the TRIZOL
reagent (Invitrogen, Carlsbad, CA) as described by the manufac-
turer. miRs were further isolated from the total RNA using a miR
isolation kit (SA Biosciences, Frederick, MD). The miR was
converted to cDNA using polyA tailing followed by universal
priming with miR First Strand Kit and quantitated using pre-
designed miR specific qPCR (SA Biosciences, Frederick, MD) on
an ABI 7900 HT Real-Time PCR system (Applied Biosystems,
Foster City, CA). mRNA quantitation was described in [46]. In
brief, cDNA was synthesized using the total RNA extracted and
the iScript cDNA Synthesis Kit, according to the manufacturer’s
protocol (Bio-Rad Laboratories). qRT-PCR was performed using
iQ SYBR Green Supermix (Bio-Rad Laboratories) on an iCycler
(BioRad) with: 95uC for 3 min followed by 40 cycles (95uC for
20 sec, 60uC for 30 sec and 72uC for 40 sec) and melting curve
step (95uC for 1 min, 55uC for 1 min, increased temperature
gradient from 50uC by 0.5uC each 10 sec in the following 80
cycles). MLH1 forward primer: GCGGCACCCACTTCCA-
GTCC; reverse: CGGAGAGTCTCATGGCACCGC. FGFR1
forward primer: GTAGCTCCCTACTGGACATCC; reverse
primer: GCATAGCGAACCTTGTAGCCTC.
miR detection and quantitation in human and mouse
blood samples
Human blood samples were obtained from the biorepository of
the Lombardi Cancer Center that collects anonymized specimen
from cancer and non-cancer patients for research purposes. The
data were analyzed anonymously. Mouse blood (,0.1 ml) was
collected via submandibular bleeding using a lancet [67]. Serum
or plasma samples were mixed at a ratio of 1:10 with Qiazol lysis
reagent and vortexed. The lysate was extracted with CHCl3 and
the aqueous phase was further processed for total RNA using the
miRNeasy Mini kit (Qiagen, Valencia, CA) and enriched for
miRNA using the RT2 qPCR-Grade miRNA Isolation Kit, MA-
01 (SABiosciences).
Gemcitabine treatment of animals
Gemcitabine was obtained from the hospital pharmacy and
administered to 22–23 month old p48-Cre/Kras
G12D or age
matched control animals at 40 mg/kg in 5 doses over the course of
one week. This dose of 200 mg/kg/week was based on Refs.
[49,50]. Blood was drawn before initiation of treatment (,0.1 ml )
and one day after the last dose. The presence of PDAC was
confirmed in the p48-Cre/Kras
G12D by postmortem histological
analysis.
Data analysis
The data processing methods were encoded in R (http://www.
r-project.org). Hierarchical clustering was performed based on the
mean centered and scaled miR expression levels. The clustering
methods used are available as pvclust [68] and sbfit [69]. These
methods allow for the calculation of significance between the
hierarchical clusters. The figure legends provide the approximately
unbiased probability (au) metrics along with P-values determining
the significance of the cluster separation. A random forest
classification algorithm [70] was applied to the data sets in an
unsupervised mode, with the number of trees set at 2000 and two
or three variables. Prism 5.0 (Graphpad-Software was used for
other tests and display of the data. Mean 6 SEM are depicted
unless indicated otherwise.
In silico miR target gene search
Four microarry studies from the Oncomine data base (http://
www.oncomine.org/) were chosen because they represented a
comparison of mRNA changes in normal or control tissues versus
pancreatic ductal adenocarcinoma [71,72,73,74]. Initially, a list of
all genes that were found downregulated in cancer tissues was
generated assuming that a miR that targets a given gene could be
reducing its steady state expression levels. Over 2500 genes were
reported as downregulated amongst the four studies chosen. This
list was shortened to 154 genes by applying the filter ‘Cancer Gene
Census – all causal cancer genes’. If a gene was downregulated
significantly (p,0.05) in one of the studies, it was searched for
possible predicted target miRs using three databases: http://
microrna.sanger.ac.uk/cgi-bin/targets/v5/search.pl, http://pictar.
mdc-berlin.de/cgi-bin/PicTar_vertebrate.cgi, http://www.targetscan.
org/ The list we report represents a possible target for the miR based
on target stringency determined by each database, with the Sanger
data base receiving the highest priority. Table S3 summarizes the
findings.
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